Related Experiment Videos
Bone disorder following partial and total gastrectomy with reference to bone mineral content
The Japanese Journal of Surgery
|March 1, 1986
Summary
Post-gastrectomy bone density loss is common, particularly after total gastrectomy and in females. Early detection of metabolic bone disorders is crucial for managing bone mineral content (BMC) after surgery.
Area of Science:
- Metabolic bone disorders
- Gastroenterology
- Endocrinology
Background:
- Gastrectomy significantly impacts nutrient absorption and metabolism.
- Metabolic bone disorders are a known complication following gastric surgery.
- Bone mineral content (BMC) and serum nutrient levels require monitoring post-gastrectomy.
Purpose of the Study:
- To investigate the incidence and characteristics of metabolic bone disorders after partial and total gastrectomy.
- To assess the relationship between gastrectomy type, surgical procedure, patient demographics, and bone health.
- To evaluate serum levels of key minerals and vitamin D in post-gastrectomy patients.
Main Methods:
- Radial bone mineral content (BMC) measurement.
- Serum analysis for calcium, inorganic phosphorus, alkaline phosphatase, and 25-hydroxyvitamin D (25-OH-D).
- Comparison of findings between partial (n=59) and total (n=39) gastrectomy patient groups.
Main Results:
- Total gastrectomy patients had a higher incidence of decreased BMC (56%) compared to partial gastrectomy (25%).
- Billroth II procedure, especially in females, was associated with abnormally low BMC.
- Bone mineral content decline was age-related and more pronounced in females.
- Low BMC was observed within 5 years for total gastrectomy and by 10 years for partial gastrectomy.
- Approximately 30% of patients exhibited abnormalities in serum minerals, alkaline phosphatase, or 25-OH-D.
Conclusions:
- Post-gastrectomy metabolic bone disorders, including decreased bone mineral content, are prevalent.
- Total gastrectomy poses a higher risk for bone density loss than partial gastrectomy.
- Female patients and those undergoing Billroth II procedure require vigilant monitoring for metabolic bone disorders and bone mineral content decline.